Understanding the genetic differences in osteosarcoma to improve treatment options
Epigenetic analysis of osteosarcoma to define subclasses relevant to chemoresistance and metastasis
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11133588
This study is looking at different types of osteosarcoma, a bone cancer that mostly affects kids and young adults, to find out how their genes work and how they might respond to treatments, so we can create better, more personalized therapies for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11133588 on ClinicalTrials.gov |
What this research studies
This research investigates osteosarcoma, a complex bone cancer primarily affecting children and young adults, by analyzing its genetic and epigenetic characteristics. The team aims to identify distinct subtypes of the disease that may respond differently to treatments, using advanced techniques like ATAC sequencing and CRISPR screens. By uncovering these subtypes and their vulnerabilities, the research seeks to develop more targeted and effective therapies, moving away from the current one-size-fits-all approach to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with osteosarcoma, particularly those who have not responded well to standard chemotherapy.
Not a fit: Patients with osteosarcoma who are not eligible for experimental treatments or those with advanced disease that has metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for osteosarcoma patients, potentially improving survival rates and reducing the side effects of chemotherapy.
How similar studies have performed: Previous research has shown promise in using epigenetic approaches to classify cancers and identify treatment vulnerabilities, suggesting that this methodology could be effective for osteosarcoma as well.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SWEET-CORDERO, ERIC ALEJANDRO — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SWEET-CORDERO, ERIC ALEJANDRO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.